FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma
Background: Lung cancer has emerged as one of the most common cancers in recent years. The mitochondrial electron transport chain (ETC) is closely connected with metabolic pathways and inflammatory response. However, the influence of ETC-associated genes on the tumor immune response and the pathogen...
Saved in:
| Published in: | Frontiers in pharmacology Vol. 12; p. 749134 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Frontiers Media S.A
08.10.2021
|
| Subjects: | |
| ISSN: | 1663-9812, 1663-9812 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background:
Lung cancer has emerged as one of the most common cancers in recent years. The mitochondrial electron transport chain (ETC) is closely connected with metabolic pathways and inflammatory response. However, the influence of ETC-associated genes on the tumor immune response and the pathogenesis of lung cancer is not clear and needs further exploration.
Methods:
The RNA-sequencing transcriptome and clinical characteristic data of LUAD were downloaded from the Cancer Genome Atlas (TCGA) database. The LASSO algorithm was used to build the risk signature, and the prediction model was evaluated by the survival analysis and receiver operating characteristic curve. We explored the function of FDX1 through flow cytometry, molecular biological methods, and liquid chromatography–tandem mass spectrometry/mass spectrometry (LC–MS/MS).
Results:
12 genes (
FDX1
,
FDX2
,
LOXL2
,
ASPH
,
GLRX2
,
ALDH2
,
CYCS
,
AKR1A1
,
MAOB
,
RDH16
,
CYBB
, and
CYB5A
) were selected to build the risk signature, and the risk score was calculated with the coefficients from the LASSO algorithm. The 1-year, 3-year, and 5-year area under the curve (AUC) of ROC curves of the dataset were 0.7, 0.674, and 0.692, respectively. Univariate Cox analysis and multivariate Cox regression analysis indicated that the risk signature is an independent risk factor for LUAD patients. Among these genes, we focused on the
FDX1
gene, and we found that knockdown of FDX1 neither inhibited tumor cell growth nor did it induce apoptosis or abnormal cell cycle distribution. But FDX1 could promote the ATP production. Furthermore, our study showed that FDX1 was closely related to the glucose metabolism, fatty acid oxidation, and amino acid metabolism.
Conclusion:
Collectively, this study provides new clues about carcinogenesis induced by ETC-associated genes in LUAD and paves the way for finding potential targets of LUAD. |
|---|---|
| AbstractList | Background: Lung cancer has emerged as one of the most common cancers in recent years. The mitochondrial electron transport chain (ETC) is closely connected with metabolic pathways and inflammatory response. However, the influence of ETC-associated genes on the tumor immune response and the pathogenesis of lung cancer is not clear and needs further exploration.
Methods: The RNA-sequencing transcriptome and clinical characteristic data of LUAD were downloaded from the Cancer Genome Atlas (TCGA) database. The LASSO algorithm was used to build the risk signature, and the prediction model was evaluated by the survival analysis and receiver operating characteristic curve. We explored the function of FDX1 through flow cytometry, molecular biological methods, and liquid chromatography–tandem mass spectrometry/mass spectrometry (LC–MS/MS).
Results: 12 genes (FDX1, FDX2, LOXL2, ASPH, GLRX2, ALDH2, CYCS, AKR1A1, MAOB, RDH16, CYBB, and CYB5A) were selected to build the risk signature, and the risk score was calculated with the coefficients from the LASSO algorithm. The 1-year, 3-year, and 5-year area under the curve (AUC) of ROC curves of the dataset were 0.7, 0.674, and 0.692, respectively. Univariate Cox analysis and multivariate Cox regression analysis indicated that the risk signature is an independent risk factor for LUAD patients. Among these genes, we focused on the FDX1 gene, and we found that knockdown of FDX1 neither inhibited tumor cell growth nor did it induce apoptosis or abnormal cell cycle distribution. But FDX1 could promote the ATP production. Furthermore, our study showed that FDX1 was closely related to the glucose metabolism, fatty acid oxidation, and amino acid metabolism.
Conclusion: Collectively, this study provides new clues about carcinogenesis induced by ETC-associated genes in LUAD and paves the way for finding potential targets of LUAD. Background: Lung cancer has emerged as one of the most common cancers in recent years. The mitochondrial electron transport chain (ETC) is closely connected with metabolic pathways and inflammatory response. However, the influence of ETC-associated genes on the tumor immune response and the pathogenesis of lung cancer is not clear and needs further exploration. Methods: The RNA-sequencing transcriptome and clinical characteristic data of LUAD were downloaded from the Cancer Genome Atlas (TCGA) database. The LASSO algorithm was used to build the risk signature, and the prediction model was evaluated by the survival analysis and receiver operating characteristic curve. We explored the function of FDX1 through flow cytometry, molecular biological methods, and liquid chromatography–tandem mass spectrometry/mass spectrometry (LC–MS/MS). Results: 12 genes ( FDX1 , FDX2 , LOXL2 , ASPH , GLRX2 , ALDH2 , CYCS , AKR1A1 , MAOB , RDH16 , CYBB , and CYB5A ) were selected to build the risk signature, and the risk score was calculated with the coefficients from the LASSO algorithm. The 1-year, 3-year, and 5-year area under the curve (AUC) of ROC curves of the dataset were 0.7, 0.674, and 0.692, respectively. Univariate Cox analysis and multivariate Cox regression analysis indicated that the risk signature is an independent risk factor for LUAD patients. Among these genes, we focused on the FDX1 gene, and we found that knockdown of FDX1 neither inhibited tumor cell growth nor did it induce apoptosis or abnormal cell cycle distribution. But FDX1 could promote the ATP production. Furthermore, our study showed that FDX1 was closely related to the glucose metabolism, fatty acid oxidation, and amino acid metabolism. Conclusion: Collectively, this study provides new clues about carcinogenesis induced by ETC-associated genes in LUAD and paves the way for finding potential targets of LUAD. Background: Lung cancer has emerged as one of the most common cancers in recent years. The mitochondrial electron transport chain (ETC) is closely connected with metabolic pathways and inflammatory response. However, the influence of ETC-associated genes on the tumor immune response and the pathogenesis of lung cancer is not clear and needs further exploration. Methods: The RNA-sequencing transcriptome and clinical characteristic data of LUAD were downloaded from the Cancer Genome Atlas (TCGA) database. The LASSO algorithm was used to build the risk signature, and the prediction model was evaluated by the survival analysis and receiver operating characteristic curve. We explored the function of FDX1 through flow cytometry, molecular biological methods, and liquid chromatography-tandem mass spectrometry/mass spectrometry (LC-MS/MS). Results: 12 genes (FDX1, FDX2, LOXL2, ASPH, GLRX2, ALDH2, CYCS, AKR1A1, MAOB, RDH16, CYBB, and CYB5A) were selected to build the risk signature, and the risk score was calculated with the coefficients from the LASSO algorithm. The 1-year, 3-year, and 5-year area under the curve (AUC) of ROC curves of the dataset were 0.7, 0.674, and 0.692, respectively. Univariate Cox analysis and multivariate Cox regression analysis indicated that the risk signature is an independent risk factor for LUAD patients. Among these genes, we focused on the FDX1 gene, and we found that knockdown of FDX1 neither inhibited tumor cell growth nor did it induce apoptosis or abnormal cell cycle distribution. But FDX1 could promote the ATP production. Furthermore, our study showed that FDX1 was closely related to the glucose metabolism, fatty acid oxidation, and amino acid metabolism. Conclusion: Collectively, this study provides new clues about carcinogenesis induced by ETC-associated genes in LUAD and paves the way for finding potential targets of LUAD.Background: Lung cancer has emerged as one of the most common cancers in recent years. The mitochondrial electron transport chain (ETC) is closely connected with metabolic pathways and inflammatory response. However, the influence of ETC-associated genes on the tumor immune response and the pathogenesis of lung cancer is not clear and needs further exploration. Methods: The RNA-sequencing transcriptome and clinical characteristic data of LUAD were downloaded from the Cancer Genome Atlas (TCGA) database. The LASSO algorithm was used to build the risk signature, and the prediction model was evaluated by the survival analysis and receiver operating characteristic curve. We explored the function of FDX1 through flow cytometry, molecular biological methods, and liquid chromatography-tandem mass spectrometry/mass spectrometry (LC-MS/MS). Results: 12 genes (FDX1, FDX2, LOXL2, ASPH, GLRX2, ALDH2, CYCS, AKR1A1, MAOB, RDH16, CYBB, and CYB5A) were selected to build the risk signature, and the risk score was calculated with the coefficients from the LASSO algorithm. The 1-year, 3-year, and 5-year area under the curve (AUC) of ROC curves of the dataset were 0.7, 0.674, and 0.692, respectively. Univariate Cox analysis and multivariate Cox regression analysis indicated that the risk signature is an independent risk factor for LUAD patients. Among these genes, we focused on the FDX1 gene, and we found that knockdown of FDX1 neither inhibited tumor cell growth nor did it induce apoptosis or abnormal cell cycle distribution. But FDX1 could promote the ATP production. Furthermore, our study showed that FDX1 was closely related to the glucose metabolism, fatty acid oxidation, and amino acid metabolism. Conclusion: Collectively, this study provides new clues about carcinogenesis induced by ETC-associated genes in LUAD and paves the way for finding potential targets of LUAD. Background: Lung cancer has emerged as one of the most common cancers in recent years. The mitochondrial electron transport chain (ETC) is closely connected with metabolic pathways and inflammatory response. However, the influence of ETC-associated genes on the tumor immune response and the pathogenesis of lung cancer is not clear and needs further exploration.Methods: The RNA-sequencing transcriptome and clinical characteristic data of LUAD were downloaded from the Cancer Genome Atlas (TCGA) database. The LASSO algorithm was used to build the risk signature, and the prediction model was evaluated by the survival analysis and receiver operating characteristic curve. We explored the function of FDX1 through flow cytometry, molecular biological methods, and liquid chromatography–tandem mass spectrometry/mass spectrometry (LC–MS/MS).Results: 12 genes (FDX1, FDX2, LOXL2, ASPH, GLRX2, ALDH2, CYCS, AKR1A1, MAOB, RDH16, CYBB, and CYB5A) were selected to build the risk signature, and the risk score was calculated with the coefficients from the LASSO algorithm. The 1-year, 3-year, and 5-year area under the curve (AUC) of ROC curves of the dataset were 0.7, 0.674, and 0.692, respectively. Univariate Cox analysis and multivariate Cox regression analysis indicated that the risk signature is an independent risk factor for LUAD patients. Among these genes, we focused on the FDX1 gene, and we found that knockdown of FDX1 neither inhibited tumor cell growth nor did it induce apoptosis or abnormal cell cycle distribution. But FDX1 could promote the ATP production. Furthermore, our study showed that FDX1 was closely related to the glucose metabolism, fatty acid oxidation, and amino acid metabolism.Conclusion: Collectively, this study provides new clues about carcinogenesis induced by ETC-associated genes in LUAD and paves the way for finding potential targets of LUAD. |
| Author | Du, Yingxi Zhang, Zeyu Wang, Xiaobing Guo, Xiaolei Zhu, Qing Duan, Changzhu Ma, Yarui |
| AuthorAffiliation | 5 Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing , China 3 Binzhou Polytechnic, Binzhou , China 4 State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing , China 2 Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing , China 1 Department of the First Clinical Medicine, Chongqing Medical University, Chongqing , China 6 Department of Cell Biology and Genetics, Medicine and Cancer Research Center, Chongqing Medical University, Chongqing , China |
| AuthorAffiliation_xml | – name: 3 Binzhou Polytechnic, Binzhou , China – name: 5 Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing , China – name: 4 State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing , China – name: 2 Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing , China – name: 1 Department of the First Clinical Medicine, Chongqing Medical University, Chongqing , China – name: 6 Department of Cell Biology and Genetics, Medicine and Cancer Research Center, Chongqing Medical University, Chongqing , China |
| Author_xml | – sequence: 1 givenname: Zeyu surname: Zhang fullname: Zhang, Zeyu – sequence: 2 givenname: Yarui surname: Ma fullname: Ma, Yarui – sequence: 3 givenname: Xiaolei surname: Guo fullname: Guo, Xiaolei – sequence: 4 givenname: Yingxi surname: Du fullname: Du, Yingxi – sequence: 5 givenname: Qing surname: Zhu fullname: Zhu, Qing – sequence: 6 givenname: Xiaobing surname: Wang fullname: Wang, Xiaobing – sequence: 7 givenname: Changzhu surname: Duan fullname: Duan, Changzhu |
| BookMark | eNp9kU1vEzEQhi1UREvpD-C2Ry4J_lqvfUGqCoVIqcoBJG7WrD2buNq1g-1U4t-zSSpEOTCXGc3M-8xI72tyFlNEQt4yuhRCm_fDbgt5ySlny04aJuQLcsGUEgujGT_7qz4nV6U80DmEMULJV-RcSGVop-kFub_9-IM1DmKzmnbgalO32HzNaRNTCaWB6Js79AEqHid3WKFPYyhTk4ZmvY-b5tpjTA6yCzFN8Ia8HGAsePWUL8n320_fbr4s1vefVzfX64Vrqa4LpbFzzmlE7BjnyiuD_VxrRUE53zqnWg6y96rtO6StHrgepKDcewqglbgkqxPXJ3iwuxwmyL9sgmCPjZQ3FnINbkTbCdSi54K1Tkpn5tOC0p4DN73smdEz68OJtdv3E3qHsWYYn0GfT2LY2k16tLqdoYLNgHdPgJx-7rFUO4XicBwhYtoXy1vdGqok4_MqO626nErJOPw5w6g9-GqPvtqDr_bk66zp_tG4UKGGdPgmjP9R_gZ99Kld |
| CitedBy_id | crossref_primary_10_3389_fgene_2022_1036460 crossref_primary_10_3389_fmed_2022_939776 crossref_primary_10_3389_fnut_2024_1410431 crossref_primary_10_1007_s00432_022_04474_4 crossref_primary_10_1186_s12885_022_10175_5 crossref_primary_10_3389_fimmu_2022_999823 crossref_primary_10_1186_s12935_024_03572_2 crossref_primary_10_1186_s12967_024_05277_6 crossref_primary_10_3390_ijms24119182 crossref_primary_10_1186_s12885_023_10714_8 crossref_primary_10_1371_journal_pone_0288180 crossref_primary_10_1186_s12885_022_10461_2 crossref_primary_10_3724_abbs_2024213 crossref_primary_10_1097_MD_0000000000031924 crossref_primary_10_3389_fnagi_2024_1480332 crossref_primary_10_3389_fonc_2023_1168769 crossref_primary_10_1155_2023_3615688 crossref_primary_10_1186_s13062_022_00340_y crossref_primary_10_3233_CBM_230341 crossref_primary_10_3389_fgene_2022_957744 crossref_primary_10_1007_s11010_023_04815_y crossref_primary_10_3389_fonc_2023_1117164 crossref_primary_10_3389_fcell_2022_989882 crossref_primary_10_3389_fonc_2022_919083 crossref_primary_10_1038_s41598_023_34752_1 crossref_primary_10_3892_or_2023_8561 crossref_primary_10_1177_09603271251335393 crossref_primary_10_3389_fgene_2022_992995 crossref_primary_10_1080_00071668_2025_2454962 crossref_primary_10_3389_fimmu_2023_1178794 crossref_primary_10_3389_fonc_2022_925411 crossref_primary_10_1155_2022_9196540 crossref_primary_10_3390_medicina59091639 crossref_primary_10_3389_fonc_2022_1085065 crossref_primary_10_3389_fcell_2022_922995 crossref_primary_10_3389_fonc_2022_922332 crossref_primary_10_3390_ijms24032244 crossref_primary_10_1155_2022_2124088 crossref_primary_10_1038_s41420_025_02553_2 crossref_primary_10_1186_s11658_024_00608_3 crossref_primary_10_1155_2022_2363043 crossref_primary_10_32604_or_2024_048562 crossref_primary_10_3389_fimmu_2022_930278 crossref_primary_10_1097_MD_0000000000040727 crossref_primary_10_32604_biocell_2024_049626 crossref_primary_10_3389_fcvm_2023_1135723 crossref_primary_10_3389_fonc_2023_927608 crossref_primary_10_1007_s10495_024_02059_9 crossref_primary_10_1002_imt2_190 crossref_primary_10_3390_jcm12185767 crossref_primary_10_3892_ol_2024_14659 crossref_primary_10_1007_s10495_023_01880_y crossref_primary_10_3390_genes13101725 crossref_primary_10_3389_fcell_2024_1459183 crossref_primary_10_2147_PGPM_S372824 crossref_primary_10_3389_fgene_2022_994741 crossref_primary_10_3390_cells12010173 crossref_primary_10_1007_s10528_025_11242_9 crossref_primary_10_1158_1055_9965_EPI_24_1096 crossref_primary_10_1186_s12885_023_11727_z crossref_primary_10_3389_fonc_2022_935672 crossref_primary_10_3390_cells14030199 crossref_primary_10_3390_biomedicines11051479 crossref_primary_10_1002_ctd2_166 crossref_primary_10_3389_fendo_2023_1135181 crossref_primary_10_3389_fgene_2022_969856 crossref_primary_10_3389_fphar_2022_938134 crossref_primary_10_5306_wjco_v14_i9_324 crossref_primary_10_1152_ajpcell_00497_2023 crossref_primary_10_3390_cells12030349 crossref_primary_10_3389_fimmu_2022_989156 crossref_primary_10_3389_fgene_2022_962028 crossref_primary_10_1007_s12031_023_02102_5 crossref_primary_10_1111_crj_13723 crossref_primary_10_3389_fgene_2023_1056000 crossref_primary_10_3389_fimmu_2022_981764 crossref_primary_10_1038_s41598_022_15251_1 crossref_primary_10_3389_fgene_2022_923737 crossref_primary_10_3389_fonc_2024_1359778 crossref_primary_10_3390_antiox13060745 crossref_primary_10_3389_fgene_2023_1071694 crossref_primary_10_1007_s00432_022_04382_7 crossref_primary_10_1002_imt2_68 crossref_primary_10_3389_fmolb_2023_963639 crossref_primary_10_1038_s41467_023_42025_8 crossref_primary_10_2147_JIR_S526096 crossref_primary_10_3389_fphar_2022_934722 crossref_primary_10_1097_MD_0000000000034230 crossref_primary_10_1007_s10238_023_01108_y crossref_primary_10_1155_2023_6232620 crossref_primary_10_3389_fphys_2024_1243629 |
| Cites_doi | 10.1038/ncomms9371 10.1016/j.cell.2016.12.039 10.1002/pmic.201900042 10.21037/tlcr.2016.06.07 10.1136/gutjnl-2020-321031 10.1016/j.cell.2011.02.013 10.5334/aogh.2419 10.1186/s12885-021-08378-3 10.1007/s00432-014-1583-9 10.1016/j.molcel.2019.08.028 10.1038/s41589-019-0291-9 10.3390/cancers13081914 10.1038/s41585-019-0185-3 10.1016/j.neo.2019.03.008 10.1016/j.intimp.2014.09.018 10.3892/mco.2018.1640 10.1038/s41568-021-00358-w 10.1073/pnas.1211502109 10.3322/caac.21492 10.1038/ni.1992 10.1186/s13046-020-01669-w 10.1016/j.mayocp.2019.01.013 10.4065/83.3.355 10.1038/nrg1708 10.1158/1541-7786.MCR-20-0579 10.3390/ijms20020252 10.1016/j.cell.2015.12.034 10.1073/pnas.1004250107 10.1016/j.bbamcr.2011.11.002 10.1016/j.omtn.2020.07.024 10.5483/bmbrep.2018.51.7.112 10.7717/peerj.11233 10.1007/s11033-020-05805-9 10.1186/s12935-021-02057-w 10.3389/fonc.2020.00424 10.1016/j.immuni.2015.09.001 10.1038/ncb3124 10.1016/j.semcdb.2019.05.018 10.1073/pnas.1019441108 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 Zhang, Ma, Guo, Du, Zhu, Wang and Duan. Copyright © 2021 Zhang, Ma, Guo, Du, Zhu, Wang and Duan. 2021 Zhang, Ma, Guo, Du, Zhu, Wang and Duan |
| Copyright_xml | – notice: Copyright © 2021 Zhang, Ma, Guo, Du, Zhu, Wang and Duan. – notice: Copyright © 2021 Zhang, Ma, Guo, Du, Zhu, Wang and Duan. 2021 Zhang, Ma, Guo, Du, Zhu, Wang and Duan |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fphar.2021.749134 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Zhang et al |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_73e83b2315c44c968e300b2a29b4b198 PMC8531531 10_3389_fphar_2021_749134 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c508t-68e7ccc8eee71226d69ebee7860a6cd5cc652a4bd65b7e058f28f4302dd0aa863 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 128 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000710949700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1663-9812 |
| IngestDate | Fri Oct 03 12:46:39 EDT 2025 Tue Sep 30 16:33:48 EDT 2025 Thu Sep 04 20:00:47 EDT 2025 Sat Nov 29 05:30:45 EST 2025 Tue Nov 18 20:27:50 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c508t-68e7ccc8eee71226d69ebee7860a6cd5cc652a4bd65b7e058f28f4302dd0aa863 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors have contributed equally to this work Edited by: Lesheng Teng, Jilin University, China Reviewed by: Yifan Ma, The Ohio State University, United States Shiyan Dong, Jilin University, China This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology |
| OpenAccessLink | https://doaj.org/article/73e83b2315c44c968e300b2a29b4b198 |
| PMID | 34690780 |
| PQID | 2585906412 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_73e83b2315c44c968e300b2a29b4b198 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8531531 proquest_miscellaneous_2585906412 crossref_primary_10_3389_fphar_2021_749134 crossref_citationtrail_10_3389_fphar_2021_749134 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-10-08 |
| PublicationDateYYYYMMDD | 2021-10-08 |
| PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationTitle | Frontiers in pharmacology |
| PublicationYear | 2021 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Bonora (B4) 2021; 13 Tsvetkov (B36) 2019; 15 Chen (B9) 2021; 21 Kumar (B26) 2019; 19 Li (B30) 2021; 21 Hanahan (B16) 2011; 144 Huang (B19) 2021 Li (B29) 2019; 21 Sher (B33) 2008; 83 Shi (B34) 2012; 1823 Zhang (B41) 2020; 21 Zhu (B42) 2019; 24 Vanhove (B38) 2019; 20 Chen (B10) 2019; 76 Duma (B13) 2019; 94 Kopinski (B25) 2021; 21 Chae (B8) 2018; 51 Liu (B31) 2020; 19 Vander Heiden (B37) 2017; 168 Hensley (B17) 2016; 164 Bi (B2) 2020; 10 Chen (B11) 2005; 6 Larman (B28) 2012; 109 Bray (B6) 2018; 68 La Vecchia (B27) 2020; 98 Huyan (B20) 2014; 23 Wang (B39) 2021; 9 Garon (B15) 2014; 140 Dinges (B12) 2019; 16 Zappa (B40) 2016; 5 Ganapathy-Kanniappan (B14) 2020; 47 Biswas (B3) 2015; 43 Boroughs (B5) 2015; 17 Ince (B21) 2000; 60 Kimura (B24) 2018; 9 Bustamante (B7) 2011; 12 Kang (B22) 2015; 6 Kanwal (B23) 2020; 39 Barta (B1) 2019; 85 Heron (B18) 2016 Sheftel (B32) 2010; 107 Strushkevich (B35) 2011; 108 |
| References_xml | – volume: 6 start-page: 8371 year: 2015 ident: B22 article-title: Regulation of NKT Cell-Mediated Immune Responses to Tumours and Liver Inflammation by Mitochondrial PGAM5-Drp1 Signalling publication-title: Nat. Commun. doi: 10.1038/ncomms9371 – volume: 168 start-page: 657 year: 2017 ident: B37 article-title: Understanding the Intersections between Metabolism and Cancer Biology publication-title: Cell doi: 10.1016/j.cell.2016.12.039 – volume: 24 start-page: 585 year: 2019 ident: B42 article-title: Correlations of Coagulation Indexes and Inflammatory Changes with the Prognosis of Lung Cancer Complicated with Thromboembolic Disease publication-title: J. BUON – volume: 19 start-page: e1900042 year: 2019 ident: B26 article-title: Challenges and Opportunities in Cancer Metabolomics publication-title: Proteomics doi: 10.1002/pmic.201900042 – start-page: 1 volume-title: Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality year: 2016 ident: B18 – volume: 5 start-page: 288 year: 2016 ident: B40 article-title: Non-small Cell Lung Cancer: Current Treatment and Future Advances publication-title: Transl Lung Cancer Res. doi: 10.21037/tlcr.2016.06.07 – start-page: 1 year: 2021 ident: B19 article-title: Ginseng Polysaccharides Alter the Gut Microbiota and Kynurenine/tryptophan Ratio, Potentiating the Antitumour Effect of Antiprogrammed Cell Death 1/programmed Cell Death Ligand 1 (Anti-PD-1/pd-L1) Immunotherapy publication-title: Gut doi: 10.1136/gutjnl-2020-321031 – volume: 144 start-page: 646 year: 2011 ident: B16 article-title: Hallmarks of Cancer: the Next Generation publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 85 start-page: 8 year: 2019 ident: B1 article-title: Global Epidemiology of Lung Cancer publication-title: Ann. Glob. Health doi: 10.5334/aogh.2419 – volume: 21 start-page: 619 year: 2021 ident: B9 article-title: Evaluation of Clinical Value and Potential Mechanism of MTFR2 in Lung Adenocarcinoma via Bioinformatics publication-title: BMC Cancer doi: 10.1186/s12885-021-08378-3 – volume: 140 start-page: 443 year: 2014 ident: B15 article-title: Dichloroacetate Should Be Considered with Platinum-Based Chemotherapy in Hypoxic Tumors rather Than as a Single Agent in Advanced Non-small Cell Lung Cancer publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-014-1583-9 – volume: 76 start-page: 838 year: 2019 ident: B10 article-title: Metabolic Diversity in Human Non-small Cell Lung Cancer Cells publication-title: Mol. Cel doi: 10.1016/j.molcel.2019.08.028 – volume: 15 start-page: 681 year: 2019 ident: B36 article-title: Mitochondrial Metabolism Promotes Adaptation to Proteotoxic Stress publication-title: Nat. Chem. Biol. doi: 10.1038/s41589-019-0291-9 – volume: 13 start-page: 1914 year: 2021 ident: B4 article-title: Mitochondrial Control of Genomic Instability in Cancer publication-title: Cancers (Basel) doi: 10.3390/cancers13081914 – volume: 16 start-page: 339 year: 2019 ident: B12 article-title: Cancer Metabolomic Markers in Urine: Evidence, Techniques and Recommendations publication-title: Nat. Rev. Urol. doi: 10.1038/s41585-019-0185-3 – volume: 60 start-page: 1261 year: 2000 ident: B21 article-title: Overexpression of Human Aspartyl (Asparaginyl) Beta-Hydroxylase Is Associated with Malignant Transformation publication-title: Cancer Res. – volume: 21 start-page: 602 year: 2019 ident: B29 article-title: ALDH2 Repression Promotes Lung Tumor Progression via Accumulated Acetaldehyde and DNA Damage publication-title: Neoplasia doi: 10.1016/j.neo.2019.03.008 – volume: 23 start-page: 452 year: 2014 ident: B20 article-title: Inhibition of Human Natural Killer Cell Functional Activity by Human Aspartyl β-hydroxylase publication-title: Int. Immunopharmacol doi: 10.1016/j.intimp.2014.09.018 – volume: 9 start-page: 201 year: 2018 ident: B24 article-title: Cost-effectiveness and Safety of the Molecular Targeted Drugs Afatinib, Gefitinib and Erlotinib as First-Line Treatments for Patients with Advanced EGFR Mutation-Positive Non-small-cell Lung Cancer publication-title: Mol. Clin. Oncol. doi: 10.3892/mco.2018.1640 – volume: 21 start-page: 431 year: 2021 ident: B25 article-title: Mitochondrial DNA Variation and Cancer publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-021-00358-w – volume: 109 start-page: 14087 year: 2012 ident: B28 article-title: Spectrum of Somatic Mitochondrial Mutations in Five Cancers publication-title: Proc. Natl. Acad. Sci. U S A. doi: 10.1073/pnas.1211502109 – volume: 68 start-page: 394 year: 2018 ident: B6 article-title: Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21492 – volume: 12 start-page: 213 year: 2011 ident: B7 article-title: Germline CYBB Mutations that Selectively Affect Macrophages in Kindreds with X-Linked Predisposition to Tuberculous Mycobacterial Disease publication-title: Nat. Immunol. doi: 10.1038/ni.1992 – volume: 39 start-page: 163 year: 2020 ident: B23 article-title: Aspartate β-hydroxylase as a Target for Cancer Therapy publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-020-01669-w – volume: 94 start-page: 1623 year: 2019 ident: B13 article-title: Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment publication-title: Mayo Clin. Proc. doi: 10.1016/j.mayocp.2019.01.013 – volume: 83 start-page: 355 year: 2008 ident: B33 article-title: Small Cell Lung Cancer publication-title: Mayo Clin. Proc. doi: 10.4065/83.3.355 – volume: 6 start-page: 815 year: 2005 ident: B11 article-title: The Organization and Inheritance of the Mitochondrial Genome publication-title: Nat. Rev. Genet. doi: 10.1038/nrg1708 – volume: 19 start-page: 667 year: 2020 ident: B31 article-title: The Ubiquitin Specific Protease USP18 Promotes Lipolysis, Fatty Acid Oxidation and Lung Cancer Growth publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-20-0579 – volume: 20 start-page: 252 year: 2019 ident: B38 article-title: Glutamine Addiction and Therapeutic Strategies in Lung Cancer publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20020252 – volume: 164 start-page: 681 year: 2016 ident: B17 article-title: Metabolic Heterogeneity in Human Lung Tumors publication-title: Cell doi: 10.1016/j.cell.2015.12.034 – volume: 107 start-page: 11775 year: 2010 ident: B32 article-title: Humans Possess Two Mitochondrial Ferredoxins, Fdx1 and Fdx2, with Distinct Roles in Steroidogenesis, Heme, and Fe/S Cluster Biosynthesis publication-title: Proc. Natl. Acad. Sci. U S A. doi: 10.1073/pnas.1004250107 – volume: 1823 start-page: 484 year: 2012 ident: B34 article-title: Both human Ferredoxins 1 and 2 and Ferredoxin Reductase Are Important for Iron-Sulfur Cluster Biogenesis publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbamcr.2011.11.002 – volume: 21 start-page: 860 year: 2020 ident: B41 article-title: Multi-omics Data Analyses Construct TME and Identify the Immune-Related Prognosis Signatures in Human LUAD publication-title: Mol. Ther. Nucleic Acids doi: 10.1016/j.omtn.2020.07.024 – volume: 51 start-page: 319 year: 2018 ident: B8 article-title: Cancer Stem Cell Metabolism: Target for Cancer Therapy publication-title: BMB Rep. doi: 10.5483/bmbrep.2018.51.7.112 – volume: 9 start-page: e11233 year: 2021 ident: B39 article-title: Identification of a Ferroptosis-Related Gene Signature (FRGS) for Predicting Clinical Outcome in Lung Adenocarcinoma publication-title: PeerJ doi: 10.7717/peerj.11233 – volume: 47 start-page: 8271 year: 2020 ident: B14 article-title: PFKP Phenotype in Lung Cancer: Prognostic Potential and beyond publication-title: Mol. Biol. Rep. doi: 10.1007/s11033-020-05805-9 – volume: 21 start-page: 339 year: 2021 ident: B30 article-title: Fatty Acid Oxidation: Driver of Lymph Node Metastasis publication-title: Cancer Cel Int doi: 10.1186/s12935-021-02057-w – volume: 10 start-page: 424 year: 2020 ident: B2 article-title: BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining publication-title: Front. Oncol. doi: 10.3389/fonc.2020.00424 – volume: 43 start-page: 435 year: 2015 ident: B3 article-title: Metabolic Reprogramming of Immune Cells in Cancer Progression publication-title: Immunity doi: 10.1016/j.immuni.2015.09.001 – volume: 17 start-page: 351 year: 2015 ident: B5 article-title: Metabolic Pathways Promoting Cancer Cell Survival and Growth publication-title: Nat. Cel Biol doi: 10.1038/ncb3124 – volume: 98 start-page: 63 year: 2020 ident: B27 article-title: Metabolic Pathways Regulating Colorectal Cancer Initiation and Progression publication-title: Semin. Cel Dev Biol doi: 10.1016/j.semcdb.2019.05.018 – volume: 108 start-page: 10139 year: 2011 ident: B35 article-title: Structural Basis for Pregnenolone Biosynthesis by the Mitochondrial Monooxygenase System publication-title: Proc. Natl. Acad. Sci. U S A. doi: 10.1073/pnas.1019441108 |
| SSID | ssj0000399364 |
| Score | 2.601976 |
| Snippet | Background:
Lung cancer has emerged as one of the most common cancers in recent years. The mitochondrial electron transport chain (ETC) is closely connected... Background: Lung cancer has emerged as one of the most common cancers in recent years. The mitochondrial electron transport chain (ETC) is closely connected... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 749134 |
| SubjectTerms | inflammatory response lung cancer metabolism mitochondria electron transport chain Pharmacology risk signature |
| Title | FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma |
| URI | https://www.proquest.com/docview/2585906412 https://pubmed.ncbi.nlm.nih.gov/PMC8531531 https://doaj.org/article/73e83b2315c44c968e300b2a29b4b198 |
| Volume | 12 |
| WOSCitedRecordID | wos000710949700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwEB21qIdeqpa26raAjFRxqEhJYscfRwqsQGJhD1Tam2U7jogECdoslbjw2xk7C2wu5cIlh9hRnJnJzBt5_AbgJ6PUUm5MopTjCZOVSBQ3PrHCBHhfGM5dbDYhzs7kbKamK62-Qk1YTw_cC25PUC-pRRRSOMac4tLTNLW5yZVlFjPm4H1ToVaSqeiDQ9zlrN_GxCxM7VU3lybwf-bZb8HCdvMgEEW-_gHIHJZIrsSc8Uf4sASLZL9f5Cd445t12Jn2bNN3u-Ti-fBUt0t2yPSZh_ruM5yPD2cZQdGRk3gUkiDWI9N5G0rr6o6YpiST2KjDx5GJX6BBXNXdNWkrcopOgOyjU8JYN3d1016bL_B3fHRxcJws-yckDmHXIkFZCeec9N6LDGFWyRWqzAvJU8NdWTjHi9wwW_LCCp8WssplxWial2VqjOT0K6w1beO_AclESOwqzkxlmUNQpaxCcFBlnhlPXTaC9FGY2i3JxUOPiyuNSUaQv47y10H-upf_CH49PXLTM2v8b_KfoKGniYEUO95AU9FLU9EvmcoIth_1q_EnCjsjpvHtbadzTJoUgrMsH4EYKH7wxuFIU19GOm4EPBg2su-vscQf8D58dV9kuAFri_mt34R37t-i7uZb8FbM5Fa0dLxO7o8eAOahA7o |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FDX1+can+Impact+the+Prognosis+and+Mediate+the+Metabolism+of+Lung+Adenocarcinoma&rft.jtitle=Frontiers+in+pharmacology&rft.au=Zhang%2C+Zeyu&rft.au=Ma%2C+Yarui&rft.au=Guo%2C+Xiaolei&rft.au=Du%2C+Yingxi&rft.date=2021-10-08&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=12&rft_id=info:doi/10.3389%2Ffphar.2021.749134&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fphar_2021_749134 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |